Health insurance companies are acting well, despite the COVID-19 pandemic, with components of negotiation in the vicinity of 2020 summits. It seems counter-intuitive, but these titles are in the “sweet spot”, as they can now increase rates without the congress or statehouse interference and compensate for the extra cost of the virus treatment. The advantage is especially powerful with Medicare Advantage plans because The Centers for Medicare and Medicaid Services (CMS) do not have the choice of sign of rate increases.
The blue-chip insurance providers are also benefiting from a second, little-known feature of the pandemic. The americans are to forego or delay treatment for other diseases to avoid the virus-ridden hospitals and waiting rooms, in a lowering of the routine payments for cardiac care and a hundred other medical conditions. Of course, the processing time makes things worse in the future, with a delay of proceedings as a routine angioplasty, potentially blooming into full-fledged open-heart surgery.
The environment policy is to give the insurers a further economic recovery in the “europe 2020” of the election. The democratic candidate Joe Biden is not in favor of a single payer system, although costly, government stimulus plans have emptied the coffers of the, making Medicare/Medicaid expansion cost-prohibitive. And all the world knows President of Asset position on national health care, with the administration still trying to dismantle Obamacare.
Dow component UnitedHealth Group Incorporated (UNH) broke out above the 2005 high of $64.61 in 2013, the seizure of a powerful upward trend, which continued with a few corrections in the December 2018 in excess of $286.53. The sellers have taken control in the first quarter of 2019, the removal of the stock for a period of 18-month low after the chief executive officer David Wichmann issued a stern warning about single-payer initiatives. The weakness of the interest of purchasers in July carved a lower-high, the configuration of a successful test the support in October.
The stock has completed a round of travel in the 2018 high in December 2019 and has erupted, but he made little progress in February. He then collapsed with the global markets, the dumping to a two-year low in the $180s in March. Impressive second quarter of the buying pressure completed a V-shaped pattern in the prior high in April, which gives a late-May breakout which failed just two weeks later, the strengthening of the resistance just above$300.
The share price moved in a trading range with support near $275, which also marks the 200-day exponential moving average (EMA). The basis of the 50-day EMA for more than two weeks and has turned higher on Thursday, the publication of three weeks. The balance volume (OBV) has been grinding through the December 2018 peak during this period, in an advantageous position for a successful escape, and the tendency to advance go up to$400.
Humana Inc. (HUM, HUM) to bounce back to the 2008 high at $88.10 in 2011, ahead of a 2013 breakout which have shown yields from the standards in June 2015, when the stock reached $219.79. It completed a cup and handle breakout at that level in May 2017, the seizure of a rising channel that contained price action in December 2018 rupture that has found support for a two-year low in the $220s in April 2019. The stock is returned to the high in December and broke out, stalling in excess of $380 in February 2020.
The decline ended a three-year low just above $200 in March, leaving room for a rebound, which was held at the same trajectory as the state of the recession. He has made a 100% retracement in April, and broke out, the display of an all-time high of $412.70 a few weeks later. The stock has just turned higher after a June test of the new support and may be soon to confirm the breakout. The Accumulation of readings to cooperate with this bullish effort, lifting to all heights as well.
The Bottom Line
Shares of health carriers may supplement the acne flare-ups, in July, in spite of the pandemic and enter into a period of the average size of the investor’s performance.
Disclosure: The author held no positions in the aforementioned securities at the time of publication.